CX-5461
Cat. No.：YN290251
CAS No. ：1138549-36-6
| 产品名称: | CX-5461 |
| CAS No.: | 1138549-36-6 |
| Chemical Name: | 2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-N-[(5-methyl-2-pyrazinyl)methyl]-5-oxo-5H-benzothiazolo[3,2-a][1,8]naphthyridine-6-carboxamide |
| Synonyms: | CX5461;CX-5461;2-(4-Methyl-1,4-diazepan-1-yl)-N-((5-methylpyrazin-2-yl)methyl)-5-oxo-5H-benzo[4,5]thiazolo[3,2-a][1,8]naphthyridine-6-carboxamide;2-(4-methyl-1,4-diazepan-1-yl)-N-[(5-methylpyrazin-2-yl)methyl]-5-oxo-[1,3]benzothiazolo[3,2-a][1,8]naphthyri |
| 分子量: | 513.61 |
| 分子式: | C₂₇H₂₇N₇O₂S |
| SMILES: | CC1=NC=C(CNC(C2=C3N(C4=NC(N5CCN(CCC5)C)=CC=C4C2=O)C6=C(S3)C=CC=C6)=O)N=C1 |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | CX-5461 是一种有效，口服的rRNA合成抑制剂。在 HCT-116，A375 和 MIA PaCa-2 细胞中抑制 RNA 聚合酶 I 驱动的 rRNA 转录，IC50为 142，113 和 54 nM。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Drygin, D., Lin, A., Bliesath, J., et al.Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growthCancer Res.71(4),1418-1430(2011)
Haddach, M., Schwaebe, M.K., Michaux, J., et al.Discovery of CX-5461, the first direct and selective inhibitor of RNA polymerase I, for cancer therapeuticsACS Med. Chem. Lett.3(7),602-606(2012)
